Home › Research › Treatments
Symptomatic lobar intracerebral hemorrhage during extended lecanemab treatment: A case report
Takahashi Y, Shiraishi N, Tsukahara A, Matsuda Y, Nishina T, Yoshikawa H, Uzu T, Mori E.. Journal of Alzheimer's disease reports, 2026-01-01
Topic: Brain proteins, microglia and lab models
Lecanemab is an anti-amyloid-β protofibril antibody that slows cognitive decline in early Alzheimer's disease. Although amyloid-related imaging abnormalities (ARIA) occur predominantly early in treatment, reports of hemorrhagic events during extended treatment beyond 18 months remain limited. A 77-year-old woman completed a standard 1.5-year lecanemab regimen without ARIA on surveillance MRIs. The day after her 42nd infusion, she acutely developed confusion and incomprehensible speech. MRI revealed a 2.5-cm left parietal subcortical hemorrhage. This case highlights that symptomatic lobar hemorrhage may occur even during extended lecanemab therapy, underscoring the importance of continued safety monitoring during extended treatment.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Takahashi, Y., Shiraishi, N., Tsukahara, A., Matsuda, Y., Nishina, T., Yoshikawa, H., et al. (2026). Symptomatic lobar intracerebral hemorrhage during extended lecanemab treatment: A case report. Journal of Alzheimer's disease reports. https://doi.org/10.1177/25424823261487915
Vancouver
Takahashi Y, Shiraishi N, Tsukahara A, Matsuda Y, Nishina T, Yoshikawa H, et al. Symptomatic lobar intracerebral hemorrhage during extended lecanemab treatment: A case report. Journal of Alzheimer's disease reports. 2026. doi:10.1177/25424823261487915. PMID: 42877463.
BibTeX
@article{takahashi2026-42877463,
author = {Takahashi, Y. and Shiraishi, N. and Tsukahara, A. and Matsuda, Y. and Nishina, T. and Yoshikawa, H. and Uzu, T. and Mori, E.},
title = {{Symptomatic lobar intracerebral hemorrhage during extended lecanemab treatment: A case report}},
journal = {Journal of Alzheimer's disease reports},
year = {2026},
doi = {10.1177/25424823261487915},
pmid = {42877463},
url = {https://doi.org/10.1177/25424823261487915}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- MRI revealed a 2.5-cm left parietal subcortical hemorrhage.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 48/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 28 of the 58 points we could judge it on, which is 48 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer's disease reports) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42877463) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 28 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 28 of the 58 points we could judge it on is 48 out of 100. |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments
Also tagged “lecanemab-treatment”
4 studies in the library carry the topic tag “lecanemab-treatment”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 4 tagged studies.